11th Conference on Retroviruses and Opportunistic Infections (CROI), 8-11 February 2004, San Francisco
2 May 2004. Related: Conference reports.
CROI 11 (Retrovirus) 2004
HIV-associated dementia and cognitive dysfunction
2 May 2004. Related: Conference reports, Coinfections and complications.
Diabetes and HIV and HCV; aging/HIV and diabetes
2 May 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Treatment with generics: tolerability, safety and resistance
5 April 2004. Related: Antiretrovirals, Treatment access.
11th Conference on Retroviruses and Opportunistic Infections (CROI)
3 April 2004. Related: Conference reports.
Drug levels can persist for more than two weeks after stopping efavirenz
3 April 2004. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Race affects absorption and clearance of efavirenz
3 April 2004. Related: Conference reports, PK and drug interactions, Side effects.
Triple PI interactions: atazanavir increases saquinavir levels in ritonavir-boosted once-daily combination
3 April 2004. Related: Conference reports, PK and drug interactions.
Triple PI interactions: fosamprenavir and Kaletra interaction is difficult to overcome
3 April 2004. Related: Conference reports, PK and drug interactions.
Ribavirin (RBV) does not alter intracellular levels of AZT, 3TC or d4T
3 April 2004. Related: Conference reports, PK and drug interactions, Hepatitis coinfection.
COLATE study shows no clinical benefit from continuing 3TC to maintain M184V mutation
3 April 2004. Related: Conference reports, Antiretrovirals.
Studies of new pipeline drugs
3 April 2004. Related: Conference reports, Antiretrovirals.
Little benefit seen for treatment during acute infection
3 April 2004. Related: Conference reports, Antiretrovirals, Basic science and immunology.
Summary of resistance studies at Retrovirus
3 April 2004. Related: Conference reports, Drug resistance.
Update on peripheral neuropathy in HIV-infection
3 April 2004. Related: Conference reports, Side effects.
Smoking marijuana provides analgesic effect on HIV neuropathy
3 April 2004. Related: Conference reports, Side effects.
Two D:A:D updates: cardiovascular risk from HAART, and predictors of hypertension and changes in blood pressure
3 April 2004. Related: Conference reports, Side effects.
Low-dose rHGH maintains reductions in abdominal fat for 60 weeks
3 April 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Rosiglitazone shows no benefit for lipoatrophy
2 April 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Hypertension related to HAART in HIV-positive women
2 April 2004. Related: Conference reports, Women's health.
Testosterone therapy for women with low androgen levels or body weight
2 April 2004. Related: Conference reports, Women's health.
Nevirapine, pregnancy and adverse events
2 April 2004. Related: Conference reports, Pregnancy.
Prior nevirapine exposure for pregnant women can contribute to treatment failure
2 April 2004. Related: Conference reports.
Conflicting findings with HAART use in pregnancy and prematurity
2 April 2004. Related: Conference reports, Pregnancy.
Antiretrovirals, mode of delivery and transmission risk
2 April 2004. Related: Conference reports, Pregnancy.
Tenofovir studies in children
2 April 2004. Related: Conference reports, Paediatric care.
Increase of non-AIDS defining cancers in HOPS cohort
2 April 2004. Related: Conference reports, Cancer and HIV.
HIV/HCV coinfection: superiority of pegylated interferon plus ribavirin, but lower response rate compared to mono-infected patients, especially for genotype-1
2 April 2004. Related: Conference reports, Hepatitis coinfection.
Epoetin-alfa improves interferon/ribavirin-associated anaemia
2 April 2004. Related: Conference reports, Hepatitis coinfection.